|Day Low/High||3.92 / 4.13|
|52 Wk Low/High||2.15 / 5.78|
Vivus' Qsymia will now be available at retail pharmacies.
A favorable FDA ruling on Qsymia's distribution is not enough for First Manhattan.
The DEA is taking its sweet time determining the abuse potential for Arena's weight-loss pill.
The $110 million loan suggests Vivus is still having trouble selling its weight loss pill.
Vivus was a winner within the drugs industry, rising 13 cents (1.2%) to $10.94 on light volume.
Vivus was a leading decliner within the drugs industry, falling 27 cents (-2.3%) to $11.27 on light volume.
Vivus was a winner within the health care sector, rising 32 cents (2.9%) to $11.42 on average volume.
Martha Stewart, Live Nation and Vivus - among others - make this week's list of the biggest business bloopers.
Here is this week's roundup of the dumbest actions on Wall Street.
Crish Lau, Kapitall Contributor Â Companies in the biotechnology space are often trade like speculative investments. Speculation for FDA approvals may [...]
Vivus was a leading decliner within the health care sector, falling $1.52 (-12.3%) to $10.89 on heavy volume.
Major U.S. stock averages rebound from the prior session's swoon.
The companies face problems with their respective weight-loss drug launches.
Major U.S. stock averages are pointing to a higher open on Wall Street Tuesday after sharp declines the prior session.
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
Institutional investor ownership flat in fourth quarter as Arena gears up to launch its weight loss pill.
The VBLOC device fails to help obese patients lose weight in a phase III study.
Soon-to-be released data will tell investors if EnteroMedics can be a player in the blockbuster obesity market.
Vivus was a leading decliner within the drugs industry, falling 59 cents (-4.5%) to $12.39 on average volume.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.